Top 10 Owners of Zomedica Corp
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| The Vanguard Group, Inc. | 4.14% | +181,358 |
| SSgA Funds Management, Inc. | 2.93% | +5,932,371 |
| BlackRock Fund Advisors | 1.19% | -5,530,082 |
| Cambridge Investment Research Adv… | 1.14% | +845 |
Similarly What does the company Zomedica do? Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians.
What is the target price for Zomedica? Stock Price Targets
| High | $1.20 |
|---|---|
| Median | $1.20 |
| Low | $1.20 |
| Average | $1.20 |
| Current Price | $0.30 |
Additionally, Is Zomedica real?
Based in Ann Arbor, Michigan., Zomedica (NYSEAMERICAN:ZOM) specializes in veterinary testing and pharmaceutical products. ZOM stock is a risky bet in the pet diagnostics field, but it’s affordable and could provide powerful gains in the long-term.
Is Vanguard invested in Zomedica?
Institutional investors has been set as your preferred Vanguard website.
…
1-50 of 4041 | Next>
| Holding | Shares | Market Value |
|---|---|---|
| Zomedica Corp. | 17,423,257 | $6,274,115 |
| Zogenix Inc. | 1,723,411 | $45,256,773 |
| Zoetis Inc. | 13,570,958 | $2,628,016,017 |
Did BlackRock buy Zom stock? – 13F, 13D, 13G Filings – Fintel.io.
…
BlackRock Inc. reports 29.83% decrease in ownership of ZOM / Zomedica Pharmaceuticals Corp.
| Security | ZOM / Zomedica Pharmaceuticals Corp. |
|---|---|
| Latest Disclosed Value | $ 3,896,000 |
Who owns the most shares of Zomedica? Largest shareholders include Vanguard Group Inc, State Street Corp, VTSMX – Vanguard Total Stock Market Index Fund Investor Shares, XHE – SPDR(R) S&P(R) Health Care Equipment ETF, VEXMX – Vanguard Extended Market Index Fund Investor Shares, BlackRock Inc., Cambridge Investment Research Advisors, Inc., Geode Capital …
How many shares does Zom have? Share Statistics
| Avg Vol (3 month) 3 | 18.11M |
|---|---|
| Shares Outstanding 5 | 979.9M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 955.44M |
| % Held by Insiders 1 | 2.63% |
Is Zomedica in Nasdaq?
Common Shares (ZOM) Stock Price, Quote, News & History | Nasdaq .
…
Key Data.
| Label | Value |
|---|---|
| Today’s High/Low | $0.34/$0.33 |
| Share Volume | 7,483,307 |
| Average Volume | 45,836,596 |
| Previous Close | $0.337 |
Should I invest in ZOM? ZOM stock is a risky bet in the pet diagnostics field, but it’s affordable and could provide powerful gains in the long-term. Or its downward spiral could continue; that’s a possibility which prospective investors should always consider.
Will ZOM recover?
ZOM stock will likely struggle to recover in price over the next few months. It’s going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
Is ZOM shorted? Short Shares Availability
This table shows the number of shares of US:ZOM available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest.
Is Zomedica expected to rise?
Zomedica Corp (NYSE American:ZOM)
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +292.16% increase from the last price of 0.31.
Why is Zomedica stock going up today?
Shares of Zomedica ( ZOM 4.97% ) climbed on Friday after the animal health specialist struck a deal to acquire Pulse Veterinary Technologies. By the close of trading today, Zomedica’s stock price was up 9.8% after rising as much as 21.2% earlier in the day.
Is ZOM undervalued? InvestorPlace’s Mark Hake estimates Zomedica (NYSEAMERICAN:ZOM) is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy at current prices.
Is Castor Maritime a good buy? Castor Maritime Inc.
holds several positive signals and is within a strong rising trend. As the old saying says, « Let the trend be your friend. ‘ ». We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by « changes at our current distributor that we believe have impacted its ability to market our products effectively. » Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Does ZOM stock have a future? Zomedica Corp (NYSE American:ZOM)
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +296.30% increase from the last price of 0.30.
Will Zomedica go up tomorrow?
Tomorrow’s movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish . This stock started moving upwards as soon as it opened.
…
Munafa value: 55 as on 08 Fri Apr 2022.
| Upside target | 0.33 |
|---|---|
| Upside target | 0.31 |
| Downside target | 0.3 |
| Downside target | 0.29 |
Who is shorting Zom? Short selling ZOM is an investing strategy that aims to generate trading profit from Zomedica as its price is falling. Zomedica’s stock is trading up $0.02 today. To short Zomedica stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender.
Why has Zomedica stock dropped?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
What is happening to Zomedica? Zomedica’s shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner’s delays. Zomedica could rebound once new assays for its Truforma instrument are available.
Is Zomedica worth buying? The Zomedica Pharmaceuticals Corp stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Should I keep Zomedica stock?
Therefore, it’s safe to say that ZOM stock is a highly speculative investment, and investors should only take small positions in this stock. Still, it’s perfectly fine to hold a few shares of ZOM stock in the hope that the company will turn itself around in 2022.
